Methods involving long lasting synthetic exendin-4-peptide conjugates
View Patent ↗Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
1. A method for treating diabetes in a subject, comprising administering to the subject a therapeutically effective amount of a compound according to the following formula:
2. The method of claim 1 , wherein said compound is in association with a physiologically acceptable medium.
3. A method for treating diabetes in a subject, comprising administering to the subject a therapeutically effective amount of a conjugate formed by reacting a compound according to the following formula:
with albumin, wherein said reacting forms a covalent bond between said compound and albumin.
4. The method of claim 3 , wherein said albumin is serum albumin.
5. The method of claim 3 , wherein said reacting occurs between said compound and cysteine 34 thiol of albumin.
6. The method of claim 3 , wherein said conjugate is in association with a physiologically acceptable medium.
7. The method of claim 4 , wherein said conjugate is in association with a physiologically acceptable medium.
8. The method of claim 5 , wherein said conjugate is in association with a physiologically acceptable medium.
9. A method for enhancing the expression of insulin in a subject, comprising administering to the subject a therapeutically effective amount of a compound according to the following formula:
10. The method of claim 9 , wherein said compound is in association with a physiologically acceptable medium.
11. A method for enhancing the expression of insulin in a subject, comprising administering to the subject a therapeutically effective amount of a conjugate formed by reacting a compound according to the following formula:
with albumin, wherein said reacting forms a covalent bond between said compound and albumin.
12. The method of claim 11 , wherein said albumin is serum albumin.
13. The method of claim 11 , wherein said reacting occurs between said compound and cysteine 34 thiol of albumin.
14. The method of claim 11 , wherein said conjugate is in association with a physiologically acceptable medium.
15. The method of claim 12 , wherein said conjugate is in association with a physiologically acceptable medium.
16. The method of claim 13 , wherein said conjugate is in association with a physiologically acceptable medium.
17. The method of any one of claims 1 - 8 , wherein the diabetes is Type II diabetes.
18. The method of claim 1 , 3 , 9 , 11 or 12 , wherein the subject is a human.
19. The method of claim 17 wherein the subject is a human.
20. The method of claim 4 , wherein said serum albumin is human serum albumin.
21. The method of claim 5 , wherein said albumin is serum albumin.
22. The method of claim 21 , wherein said conjugate is in association with a physiologically acceptable medium.
23. The method of claim 22 , wherein the subject is a human.
24. The method of claim 23 , wherein the diabetes is Type II diabetes.
25. The method of claim 5 , wherein said albumin is human serum albumin.
26. The method of claim 25 , wherein said conjugate is in association with a physiologically acceptable medium.
27. The method of claim 26 , wherein the subject is a human.
28. The method of claim 27 , wherein the diabetes is Type II diabetes.
29. The method of claim 12 , wherein said serum albumin is human serum albumin.
30. The method of claim 13 , wherein said albumin is serum albumin.
31. The method of claim 30 , wherein said conjugate is in association with a physiologically acceptable medium.
32. The method of claim 31 , wherein the subject is a human.
33. The method of claim 32 , wherein the subject has Type II diabetes.
34. The method of claim 13 , wherein said albumin is human serum albumin.
35. The method of claim 34 , wherein said conjugate is in association with a physiologically acceptable medium.
36. The method of claim 35 , wherein the subject is a human.
37. The method of claim 36 , wherein the subject has Type II diabetes.